CRISPR/Cas-based Diagnostics and Gene Therapy
Clustered regularly interspaced short palindromic repeats (CRISPR) technology, an easy, rapid, cost-effective, and precise gene-editing technique, has revolutionized diagnostics and gene therapy. Fast and accurate diagnosis of diseases is essential for point-of-care-testing (POCT) and specialized me...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2021-11-01
|
| Series: | BIO Integration |
| Subjects: | |
| Online Access: | https://www.ingentaconnect.com/contentone/cscript/bioi/2021/00000002/00000003/art00004 |
| _version_ | 1811158999619338240 |
|---|---|
| author | Meiyu Qiu Pei Li |
| author_facet | Meiyu Qiu Pei Li |
| author_sort | Meiyu Qiu |
| collection | DOAJ |
| description | Clustered regularly interspaced short palindromic repeats (CRISPR) technology, an easy, rapid, cost-effective, and precise gene-editing technique, has revolutionized diagnostics and gene therapy. Fast and accurate diagnosis of diseases is essential for point-of-care-testing (POCT) and specialized medical institutes. The CRISPR-associated (Cas) proteins system shed light on the new diagnostics methods at point-of-care (POC) owning to its advantages. In addition, CRISPR/Cas-based gene-editing technology has led to various breakthroughs in gene therapy. It has been employed in clinical trials for a variety of untreatable diseases, including cancer, blood disorders, and other syndromes. Currently, the clinical application of CRISPR/Cas has been mainly focused on ex vivo therapies. Recently, tremendous efforts have been made in the development of ex vivo gene therapy based on CRISPR-Cas9. Despite these efforts, in vivo CRISPR/Cas gene therapy is only in its initial stage. Here, we review the milestones of CRISPR/Cas technologies that advanced the field of diagnostics and gene therapy. We also highlight the recent advances of diagnostics and gene therapy based on CRISPR/Cas technology. In the last section, we discuss the strength and significant challenges of the CRISPR/Cas technology for its future clinical usage in diagnosis and gene therapy. |
| first_indexed | 2024-04-10T05:33:44Z |
| format | Article |
| id | doaj.art-b0aa443351d542798090fad645ccac65 |
| institution | Directory Open Access Journal |
| issn | 2712-0082 |
| language | English |
| last_indexed | 2024-04-10T05:33:44Z |
| publishDate | 2021-11-01 |
| publisher | Compuscript Ltd |
| record_format | Article |
| series | BIO Integration |
| spelling | doaj.art-b0aa443351d542798090fad645ccac652023-03-07T04:03:33ZengCompuscript LtdBIO Integration2712-00822021-11-012312112910.15212/bioi-2020-0048CRISPR/Cas-based Diagnostics and Gene TherapyMeiyu Qiu0Pei Li1Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of KoreaDepartment of Materials Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of KoreaClustered regularly interspaced short palindromic repeats (CRISPR) technology, an easy, rapid, cost-effective, and precise gene-editing technique, has revolutionized diagnostics and gene therapy. Fast and accurate diagnosis of diseases is essential for point-of-care-testing (POCT) and specialized medical institutes. The CRISPR-associated (Cas) proteins system shed light on the new diagnostics methods at point-of-care (POC) owning to its advantages. In addition, CRISPR/Cas-based gene-editing technology has led to various breakthroughs in gene therapy. It has been employed in clinical trials for a variety of untreatable diseases, including cancer, blood disorders, and other syndromes. Currently, the clinical application of CRISPR/Cas has been mainly focused on ex vivo therapies. Recently, tremendous efforts have been made in the development of ex vivo gene therapy based on CRISPR-Cas9. Despite these efforts, in vivo CRISPR/Cas gene therapy is only in its initial stage. Here, we review the milestones of CRISPR/Cas technologies that advanced the field of diagnostics and gene therapy. We also highlight the recent advances of diagnostics and gene therapy based on CRISPR/Cas technology. In the last section, we discuss the strength and significant challenges of the CRISPR/Cas technology for its future clinical usage in diagnosis and gene therapy.https://www.ingentaconnect.com/contentone/cscript/bioi/2021/00000002/00000003/art00004clinical trailscrispr/casdiagnosticsgene therapypoint-of-care-testing |
| spellingShingle | Meiyu Qiu Pei Li CRISPR/Cas-based Diagnostics and Gene Therapy BIO Integration clinical trails crispr/cas diagnostics gene therapy point-of-care-testing |
| title | CRISPR/Cas-based Diagnostics and Gene Therapy |
| title_full | CRISPR/Cas-based Diagnostics and Gene Therapy |
| title_fullStr | CRISPR/Cas-based Diagnostics and Gene Therapy |
| title_full_unstemmed | CRISPR/Cas-based Diagnostics and Gene Therapy |
| title_short | CRISPR/Cas-based Diagnostics and Gene Therapy |
| title_sort | crispr cas based diagnostics and gene therapy |
| topic | clinical trails crispr/cas diagnostics gene therapy point-of-care-testing |
| url | https://www.ingentaconnect.com/contentone/cscript/bioi/2021/00000002/00000003/art00004 |
| work_keys_str_mv | AT meiyuqiu crisprcasbaseddiagnosticsandgenetherapy AT peili crisprcasbaseddiagnosticsandgenetherapy |